Capital Counsel LLC NY Lowers Position in Thermo Fisher Scientific Inc. $TMO

Capital Counsel LLC NY decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 28.7% during the second quarter, Holdings Channel reports. The fund owned 804 shares of the medical research company’s stock after selling 323 shares during the period. Capital Counsel LLC NY’s holdings in Thermo Fisher Scientific were worth $326,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in Thermo Fisher Scientific by 0.9% during the second quarter. Vanguard Group Inc. now owns 33,789,164 shares of the medical research company’s stock valued at $13,700,154,000 after buying an additional 309,207 shares during the period. Norges Bank purchased a new position in Thermo Fisher Scientific during the 2nd quarter valued at about $2,264,615,000. Franklin Resources Inc. boosted its stake in Thermo Fisher Scientific by 11.3% during the second quarter. Franklin Resources Inc. now owns 4,897,546 shares of the medical research company’s stock worth $1,985,759,000 after acquiring an additional 498,238 shares in the last quarter. Amundi grew its holdings in Thermo Fisher Scientific by 5.9% in the first quarter. Amundi now owns 3,029,044 shares of the medical research company’s stock worth $1,426,316,000 after purchasing an additional 168,197 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Thermo Fisher Scientific by 2.6% during the second quarter. Charles Schwab Investment Management Inc. now owns 3,000,562 shares of the medical research company’s stock valued at $1,216,612,000 after purchasing an additional 74,971 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $591.99 on Monday. The firm has a market capitalization of $222.42 billion, a PE ratio of 34.20, a P/E/G ratio of 3.27 and a beta of 0.82. The company has a 50 day moving average price of $548.54 and a 200-day moving average price of $480.12. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.50 by $0.29. The company had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The firm’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter last year, the company posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.94%.

Thermo Fisher Scientific announced that its board has initiated a stock buyback plan on Thursday, November 6th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to buy up to 2.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on TMO. TD Cowen raised their price objective on Thermo Fisher Scientific from $612.00 to $654.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Evercore ISI raised their price target on Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. Citigroup upped their price target on shares of Thermo Fisher Scientific from $500.00 to $580.00 and gave the stock a “neutral” rating in a research note on Thursday, October 23rd. Barclays lifted their target price on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Finally, Redburn Partners set a $580.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, October 8th. Nineteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $601.65.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Friday, October 24th. The shares were sold at an average price of $574.15, for a total transaction of $229,660.00. Following the completion of the sale, the executive vice president owned 21,152 shares of the company’s stock, valued at $12,144,420.80. This represents a 1.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Lisa P. Britt sold 1,058 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $588.26, for a total transaction of $622,379.08. Following the completion of the transaction, the vice president directly owned 13,087 shares in the company, valued at approximately $7,698,558.62. The trade was a 7.48% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 51,800 shares of company stock worth $30,003,027. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.